Stock Analysis, Dividends, Split History

HAIN / Hain Celestial Group, Inc. (The) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,878.43
Enterprise Value ($M)3,512.59
Book Value ($M)1,737.05
Book Value / Share16.71
Price / Book1.66
NCAV ($M)-158.04
NCAV / Share-1.52
Price / NCAV-18.21
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 103,952,111
Common Stock Shares Outstanding 103,952,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.01
Balance Sheet (mrq) ($M)
Quick Ratio1.56
Current Ratio2.49
Income Statement (mra) ($M)
Sales Revenue Net0.00
Operating Income106.04
Net Income9.69
Earnings Per Share Diluted0.09
Earnings Per Share Basic0.09
Cash Flow Statement (mra) ($M)
Cash From Operations121.31
Cash from Investing-82.52
Cash from Financing-82.52
Identifiers and Descriptors
Central Index Key (CIK)910406
Related CUSIPS
405000000 405217950 405217900

Split History

Stock splits are used by Hain Celestial Group, Inc. (The) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Patience Is Key With Hain Celestial

2018-09-11 seekingalpha
Strategic initiatives taken by the company are laying the groundwork for significant profit growth over the next few years. (36-0)

Trade of the Day: Hain Celestial Group Inc (HAIN)

2018-08-31 investorplace
To receive further updates on this Hain Celestial Group Inc (NASDAQ:HAIN) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today. (1-0)

What Will Coca-Cola Acquire Next?

2018-08-31 247wallst
With its $5 billion acquisition of the Costa coffee shop chain, Coca-Cola Co. (NYSE: KO) once more has shown its commitment to expanding its footprint and the diversity of its offerings through bolt-on acquisitions. Investors must be asking themselves what’s next. (23-2)

Hain Celestial (HAIN) Q4 Earnings Decline Y/Y, Stock Down

2018-08-29 zacks
The Hain Celestial Group, Inc. (HAIN - Free Report) reported fourth-quarter fiscal 2018 results, wherein sales marked its third consecutive miss. Also, the bottom line fell year over year, which can be accountable to elevated promotions and freight costs that hurt the company’s gross margin. Consequently, shares of Hain Celestial lost 6.4% yesterday, taking its year-to-date performance to a slump of almost 37% compared with the industry’s drop of 5. (9-0)

The Hain Celestial Group, Inc. (HAIN) CEO Irwin Simon on Q4 2018 Results - Earnings Call Transcript

2018-08-28 seekingalpha
The Hain Celestial Group, Inc. (NASDAQ:HAIN) Q4 2018 Earnings Conference Call August 28, 2018 8:30 AM ET (3-0)

CUSIP: 405217100